Published in J Virol on January 21, 2009
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med (2015) 2.28
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ (2012) 1.71
The global transmission network of HIV-1. J Infect Dis (2013) 1.68
Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections. BMC Infect Dis (2010) 1.64
Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysis. J Virol (2011) 1.55
Phylogenetic insights into regional HIV transmission. AIDS (2012) 1.18
Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr (2012) 1.11
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10
Phylogenetic studies of transmission dynamics in generalized HIV epidemics: an essential tool where the burden is greatest? J Acquir Immune Defic Syndr (2014) 1.03
HIV Type 1 transmission networks among men having sex with men and heterosexuals in Kenya. AIDS Res Hum Retroviruses (2013) 1.03
Inhibition of HIV-1 replication by isoxazolidine and isoxazole sulfonamides. Chem Biol Drug Des (2010) 1.02
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation. J Med Chem (2010) 0.98
Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein. J Biol Chem (2010) 0.94
Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology (2011) 0.92
Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther (2011) 0.89
Searching for virus phylotypes. Bioinformatics (2013) 0.89
Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr (2012) 0.89
Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecks. Sci Rep (2012) 0.87
HIV-1 subtype D infections among Caucasians from Northwestern Poland--phylogenetic and clinical analysis. PLoS One (2012) 0.87
Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands. Org Biomol Chem (2014) 0.86
Future of phylogeny in HIV prevention. J Acquir Immune Defic Syndr (2013) 0.85
Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies. J Med Chem (2013) 0.84
Reconstructing the timing and dispersion routes of HIV-1 subtype B epidemics in the Caribbean and Central America: a phylogenetic story. PLoS One (2013) 0.83
Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors. Bioorg Med Chem Lett (2012) 0.80
Molecular typing of the recently expanding subtype B HIV-1 epidemic in Romania: evidence for local spread among MSMs in Bucharest area. Infect Genet Evol (2012) 0.80
Understanding drivers of phylogenetic clustering in molecular epidemiological studies of HIV. J Infect Dis (2014) 0.78
Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions. BMC Infect Dis (2013) 0.77
Highly active antiretroviral therapy is associated with decreased incidence of sexually transmitted diseases in a Taiwanese HIV-positive population. AIDS Patient Care STDS (2013) 0.77
Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies. J Med Chem (2015) 0.77
Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands. Bioorg Med Chem Lett (2015) 0.76
Interplay Between Transmitted and Acquired HIV Type 1 Drug Resistance: Reasons for a Disconnect. J Infect Dis (2015) 0.75
Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy. PLoS One (2015) 0.75
Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation. J Clin Microbiol (2016) 0.75
Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands. Org Biomol Chem (2015) 0.75
Multi-scale immunoepidemiological modeling of within-host and between-host HIV dynamics: systematic review of mathematical models. PeerJ (2017) 0.75
Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex. Bioorg Med Chem (2017) 0.75
Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands. Bioorg Med Chem Lett (2017) 0.75
Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants. J Med Chem (2017) 0.75
BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol (2007) 74.13
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci (1997) 45.07
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
A general empirical model of protein evolution derived from multiple protein families using a maximum-likelihood approach. Mol Biol Evol (2001) 16.83
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
Bayesian selection of continuous-time Markov chain evolutionary models. Mol Biol Evol (2001) 8.69
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics (2005) 5.60
A space-time process model for the evolution of DNA sequences. Genetics (1995) 5.56
Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med (2008) 4.76
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis (1995) 4.60
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
HIV chemotherapy. Nature (2001) 3.63
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci U S A (2000) 2.61
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol (1998) 2.50
The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol (2006) 2.10
Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther (2007) 1.93
Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS (2007) 1.81
Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS (2008) 1.74
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med (2006) 1.73
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS (1999) 1.65
Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol (2007) 1.57
Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS (2007) 1.46
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS (2007) 1.28
Emerging drug targets for antiretroviral therapy. Drugs (2005) 1.26
Transmission of HIV-1 drug resistance. J Clin Virol (2004) 1.24
Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol (2000) 1.24
Raltegravir: an integrase inhibitor for HIV-1. Expert Opin Investig Drugs (2008) 1.18
Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis (2006) 1.07
A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry (1996) 0.97
Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249. AIDS Res Hum Retroviruses (2007) 0.93
Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am J Med (1988) 0.91
Reversion from zidovudine resistance to sensitivity on cessation of treatment. Lancet (1991) 0.90
Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable. Lancet (1999) 0.88
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry (2002) 3.89
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis (2009) 3.37
Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis (2013) 3.35
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis (2008) 3.15
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups. Proc Natl Acad Sci U S A (2005) 3.04
Endogenous viral elements in animal genomes. PLoS Genet (2010) 2.97
Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog (2009) 2.92
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology (2010) 2.90
Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
Discovery and analysis of the first endogenous lentivirus. Proc Natl Acad Sci U S A (2007) 2.43
HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS (2004) 2.35
Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci U S A (2009) 2.21
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog (2009) 2.10
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med (2005) 2.04
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis (2009) 1.96
Ten years of bacterial genome sequencing: comparative-genomics-based discoveries. Funct Integr Genomics (2006) 1.86
Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med (2005) 1.83
Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS (2010) 1.82
The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics (2009) 1.80
Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology (2008) 1.79
A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry (2005) 1.74
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ (2012) 1.71
Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis (2010) 1.70
Macroevolution of complex retroviruses. Science (2009) 1.63
Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med (2004) 1.62
Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr (2004) 1.61
Optimal use of maraviroc in clinical practice. AIDS (2008) 1.60
Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol (2007) 1.57
The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS (2002) 1.50
Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS (2007) 1.46
Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis (2005) 1.46
Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J Clin Microbiol (2012) 1.45
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther (2008) 1.41
Limitations of proposed novel trial design. AIDS (2012) 1.39
Drug resistance mutations in HIV-1. Top HIV Med (2004) 1.37
Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J Virol (2009) 1.37
World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther (2008) 1.36
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis (2010) 1.36
The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr (2008) 1.35
Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis (2004) 1.35
Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog (2013) 1.35
Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet (2004) 1.33
Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J (2006) 1.33
Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS (2010) 1.29
Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS (2007) 1.28
Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol (2008) 1.27
Data linkage reduces loss to follow-up in an observational HIV cohort study. J Clin Epidemiol (2010) 1.26
Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis (2013) 1.26
Transmission of HIV-1 drug resistance. J Clin Virol (2004) 1.24
Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS (2009) 1.23
The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PLoS One (2010) 1.19
Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial. J Child Adolesc Psychopharmacol (2013) 1.19
Phylogenetic insights into regional HIV transmission. AIDS (2012) 1.18
Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav (2012) 1.14
Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS (2006) 1.14